Brief: Atyr Pharma Announces Publication Of Positive Data From Phase 1B/2A Clinical Study Of Efzofitimod
09/11/2022 15:28
Nov 9 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA ANNOUNCES PUBLICATION OF POSITIVE DATA FROM
PHASE
1B/2A CLINICAL STUDY OF EFZOFITIMOD FOR THE TREATMENT OF
PULMONARY SARCOIDOSIS IN THE JOURNAL CHEST
* ATYR PHARMA INC - GLOBAL PIVOTAL PHASE 3 EFZO-FIT™ STUDY
CURRENTLY ENROLLING
Source text for Eikon: ID:nGNXbQTWFF
Further company coverage: LIFE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan